Baicalin ameliorates neuropathic pain by suppressing HDAC1 expression in the spinal cord of spinal nerve ligation rats

Journal of the Formosan Medical Association

Volumn 113, Issue 8, 2014, Pages 513-520

  Cherng, Chen Hwan ^a   Lee, Kwong Chiu ^b   Chien, Chih Cheng ^c   Chou, Kuang Yi ^d   Cheng, Yu Che ^c,e   Hsin, Shih Tai ^f   Lee, Sing Ong ^c   Shen, Ching Hui ^g   Tsai, Ru Yin ^c,d   Wong, Chih Shung ^c,f,h  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^e NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^f NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^g TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^h FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

Acetylation; Histone; Intrathecal injection; Morphine; Neuropathy

Indexed keywords

ANTINOCICEPTIVE AGENT; BAICALIN; HISTONE DEACETYLASE 1; MORPHINE; FLAVONOID; HDAC1 PROTEIN, RAT; HISTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; ENZYME REPRESSION; EPIGENETICS; MALE; NEUROPATHIC PAIN; NONHUMAN; RANDOMIZATION; RAT; SPINAL CORD DORSAL HORN; SPINAL NERVE LIGATION INJURY; ACETYLATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; GENETICS; HYPERALGESIA; INJURIES; INTRASPINAL DRUG ADMINISTRATION; LIGATION; METABOLISM; NEURALGIA; PAIN MEASUREMENT; SPINAL CORD; SPINAL NERVE; WISTAR RAT;

ACETYLATION; ANIMALS; FLAVONOIDS; HISTONE DEACETYLASE 1; HISTONES; HYPERALGESIA; INJECTIONS, SPINAL; LIGATION; MALE; MORPHINE; NEURALGIA; PAIN MEASUREMENT; RATS; RATS, WISTAR; SPINAL CORD; SPINAL NERVES;

EID: 84904392374     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2013.04.007     Document Type: Article

References (41)

1. Campbell J.N., Meyer R.A. Mechanisms of neuropathic pain. Neuron 2006, 52:77-92.
2. Griffin R.S., Costigan M., Brenner G.J., Ma C.H., Scholz J., Moss A., et al. Complement induction in spinal cord microglia results in anaphylatoxin C5a-mediated pain hypersensitivity. J Neurosci 2007, 27:8699-8708.
3. Doehring A., Geisslinger G., Lotsch J. Epigenetics in pain and analgesia: an imminent research field. Eur J Pain 2011, 15:11-16.
4. Denk F., McMahon S.B. Chronic pain: emerging evidence for the involvement of epigenetics. Neuron 2012, 73:435-444.
5. Selvi B.R., Mohankrishna D.V., Ostwal Y.B., Kundu T.K. Small molecule modulators of histone acetylation and methylation: a disease perspective. Biochim Biophys Acta 2010, 1799:810-828.
6. Leoni F., Fossati G., Lewis E.C., Lee J.K., Porro G., Pagani P., et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines invitro and systemic inflammation invivo. Mol Med 2005, 11:1-15.
7. Li Y., Reddy M.A., Miao F., Shanmugam N., Yee J.K., Hawkins D., et al. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem 2008, 283:26771-26781.
8. Marchand F., Perretti M., McMahon S.B. Role of the immune system in chronic pain. Nat Rev Neurosci 2005, 6:521-532.
9. Lin C.C., Shieh D.E. The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chinese Med 1996, 24:31-36.
10. Gao Z., Huang K., Yang X., Xu H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta 1999, 1472:643-650.
11. Chung Y.L., Lee M.Y., Wang A.J., Yao L.F. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003, 8:707-717.
12. Tsai R.Y., Chou K.Y., Shen C.H., Chien C.C., Tsai W.Y., Huang Y.N., et al. Resveratrol regulates N-methyl-d-aspartate receptor expression and suppresses neuroinflammation in morphine-tolerant rats. Anesth Analg 2012, 115:944-952.
13. Lin Y.S., Tsai R.Y., Shen C.H., Chien C.C., Tsai W.Y., Guo S.L., et al. Ultra-low dose naloxone restores the antinocicepitve effect of morphine in PTX-treated rats: association of IL-10 upregulation in the spinal cord. Life Sciences 2012, 91:213-220.
14. Tsai R.Y., Tai Y.H., Tzeng J.I., Cherng C.H., Yeh C.C., Wong C.S. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein. Neuroscience 2009, 164:435-443.
15. Tsai R.Y., Tai Y.H., Tzeng J.I., Lin S.L., Shen C.H., Yang C.P., et al. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats and prevents glutamate transporter downregulation by suppressing the p38 mitogen-activated protein kinase signaling pathway. Neuroscience 2009, 159:1244-1256.
16. Kim S.H., Chung J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992, 50:355-363.
17. Loeser J.D., Treede R.D. The Kyoto protocol of IASP Basic Pain Terminology. Pain 2008, 137:473-477.
18. Yang C.P., Cherng C.H., Wu C.T., Huang H.Y., Tao P.L., Wong C.S. Intrathecal ultra-low dose naloxone enhances the antinociceptive effect of morphine by enhancing the reuptake of excitatory amino acids from the synaptic cleft in the spinal cord of partial sciatic nerve-transected rats. Anesth Analg 2011, 113:1490-1500.
19. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
20. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10:32-42.
21. Lucio-Eterovic A.K., Cortez M.A., Valera E.T., Motta F.J., Queiroz R.G., Machado H.R., et al. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008, 8:243.
22. Renthal W., Maze I., Krishnan V., Covington H.E., Xiao G., Kumar A., et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 2007, 56:517-529.
23. Glauben R., Batra A., Fedke I., Zeitz M., Lehr H.A., Leoni F., et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006, 176:5015-5022.
24. Ma B.B., Sung F., Tao Q., Poon F.F., Lui V.W., Yeo W., et al. The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs 2010, 28:107-114.
25. Bai G., Wei D., Zou S., Ren K., Dubner R. Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia. Molecular Pain 2010, 6:51.
26. Chiechio S., Copani A., Zammataro M., Battaglia G., Gereau R.W., Nicoletti F. Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. Trends Pharmacol Sci 2010, 31:153-160.
27. Bradner J.E., West N., Grachan M.L., Greenberg E.F., Haggarty S.J., Warnow T., et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010, 6:238-243.
28. Rajan I., Savelieva K.V., Ye G.L., Wang C.Y., Malbari M.M., Friddle C., et al. Loss of the putative catalytic domain of HDAC4 leads to reduced thermal nociception and seizures while allowing normal bone development. PloS One 2009, 4:e6612.
29. Bi J., Hu X., Loh H.H., Wei L.N. Regulation of mouse kappa opioid receptor gene expression by retinoids. J Neurosci 2001, 21:1590-1599.
30. Lin Y.C., Flock K.E., Cook R.J., Hunkele A.J., Loh H.H., Ko J.L. Effects of trichostatin A on neuronal mu-opioid receptor gene expression. Brain Res 2008, 1246:1-10.
31. Chiechio S., Zammataro M., Morales M.E., Busceti C.L., Drago F., Gereau R.W., et al. Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain. Mol Pharmacol 2009, 75:1014-1020.
32. Crain S.M., Shen K.F. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 2000, 84:121-131.
33. Wen Y.R., Tan P.H., Cheng J.K., Liu Y.C., Ji R.R. Microglia: a promising target for treating neuropathic and postoperative pain, and morphine tolerance. J Formosan Med Assoc 2011, 110:487-494.
34. Raghavendra V., Tanga F., DeLeo J.A. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 2003, 306:624-630.
35. Watkins L.R., Hutchinson M.R., Ledeboer A., Wieseler-Frank J., Milligan E.D., Maier S.F. Norman Cousins Lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 2007, 21:131-146.
36. Watkins L.R., Maier S.F. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003, 2:973-985.
37. Ji R.R., Suter M.R. p38 MAPK, microglial signaling, and neuropathic pain. Molecular Pain 2007, 3:33-42.
38. Tsai R.Y., Jang F.L., Tai Y.H., Lin S.L., Shen C.H., Wong C.S. Ultra-low-dose naloxone restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in PTX-treated rats. Neuropsychopharmacology 2008, 33:2772-2782.
39. Tsai R.Y., Shen C.H., Feng Y.P., Chien C.C., Lee S.O., Tsai W.Y., et al. Ultra-low-dose naloxone enhances the antinociceptive effect of morphine in PTX-treated rats: regulation on global histone methylation. Acta Anaesthesiol 2012, 50:106-111.
40. Chou T.C., Chang L.P., Li C.Y., Wong C.S., Yang S.P. The antiinflammatory and analgesic effects of baicalin in carrageenan-evoked thermal hyperalgesia. Anesth Analg 2003, 97:1724-1729.
41. Li H.Y., Yuan Z.Y., Wang Y.G., Wan H.J., Hu J., Chai Y.S., et al. Role of baicalin in regulating Toll-like receptor 2/4 after ischemic neuronal injury. Chinese Med J 2012, 125:1586-1593.